Commentary

Video

NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection

Andrew G. Lee, MD, and Drew Carey, MD, return for this latest episode of the "NeuroOp Guru" to discuss the variable presentations of somatic mitochondrial mutations and the importance of muscle biopsy in diagnosing low heteroplasmy in mitochondrial diseases.

This latest episode of the “NeuroOp Guru”—hosted by Andrew G. Lee, MD, from Houston Methodist, and joined by Drew Carey, MD, from Johns Hopkins University—features a retrospective study1 on somatic mitochondrial mutations and their variable neuro-ophthalmic manifestations.

Mitochondrial diseases are typically inherited maternally, but mutations can also arise post-fertilization and affect specific tissues. These somatic mutations may present with mild symptoms like muscle manifestations or isolated optic neuropathy, without the full spectrum of mitochondrial disease features (eg, seizures or cardiac issues).

Traditionally, high heteroplasmy (a higher percentage of affected mitochondria) was thought to be necessary for symptoms to manifest, but this study challenges that view.

Even low heteroplasmy (less than 5%) may cause disease, particularly in tissues like the optic nerve or extraocular muscles, which might show higher heteroplasmy despite muscle biopsies showing low levels. The take-home message is that mitochondrial disease can present variably, and muscle biopsy should be considered if genetic testing is inconclusive, especially when muscle-based symptoms are predominant.

Reference
  1. Carey AR, Miller NR, Cui H, et al. Myopathy and ophthalmologic abnormalities in association with multiple skeletal muscle mitochondrial DNA deletions. J Neuroophthalmol. 2024;44(2):247-252. doi:10.1097/WNO.0000000000001984

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexyloctane in dry eye
(Image credit: Ophthalmology Times) CCOI's new CEO Malvina Eydelman, MD, outlines her mission and vision for the organization
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
© 2025 MJH Life Sciences

All rights reserved.